In Week of Mar 28, 2026, Axentra Corp Limited (Construction - Factories/Offices/Commercial) is outperforming Nifty 500 with +7.7% relative strength. Fundamentals: Very Weak. On a 5-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Feb 28, 2026
What: 18.46% YoY growth in pharma segment outpacing chemical segment
Impact: +₹35 Cr revenue
“Pharmaceutical segment generated revenue of ₹356.05 crore compared to ₹300.58 crore in Q3 FY25”
What: Inventory reduction initiatives improving cash flow
“We do expect further inventory reductions into the fourth quarter... another sort of $15-$20 million”
What: Expense management translating low growth to bottom line
“In a low-growth environment, a lot of that's going to fall directly to the bottom line”
Earnings deceleration risks from management commentary
Trigger: Continued input cost pressures
Impact: -50 bps margin impact
Management view: Gross profit margin is being well-managed but OPM still declined YoY
Monitor: OPM trend in Q4 FY26
Trigger: Full implementation of wage definition changes
Impact: -70 bps margin impact
Management view: Exceptional items arising from changes in wage definition following Labour Codes notification
Monitor: Wage expenses in Q4 FY26
Key quotes from recent conference calls
“Pharmaceutical segment generated revenue of ₹356.05 crore compared to ₹300.58 crore in Q3 FY25 — Management”
“We do expect further inventory reductions into the fourth quarter. We took a good chunk out in the third quarter, and I think there's some more to go. — Faiz Karmally, VP & CFO”
“When we do see, even if it's kind of a low-growth environment, I think a lot of that's going to fall directly to the bottom line. — Faiz Karmally, VP & CFO”
“The company reported exceptional items worth ₹11.21 crore in Q3 FY26, primarily arising from changes in wage definition following the notification of four Labour Codes — Management”
Forward-looking targets from management for Q4 FY26
Revenue Growth Target
10%
Implied PAT Growth
5%
OPM Guidance
3.5%
Key Milestones
• Pharmaceutical segment growth continuation
• Working capital optimization completion
• Labour Code implementation impact assessment
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| PAT (Net Profit) | -67% | +80% | Stable |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Feb 28, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Axentra Corp Limited's latest quarterly results (Dec 2025) show
Axentra Corp Limited's profit is declining with an stable trend.
Axentra Corp Limited's revenue growth trend is insufficient_data.
Axentra Corp Limited's operating margin is insufficient_data.
Axentra Corp Limited's long-term compounding rates
Axentra Corp Limited's earnings growth is stable with mixed signals on a sequential basis.
Axentra Corp Limited's trailing twelve month (TTM) performance
Axentra Corp Limited appears significantly overvalued based on our fair value analysis.
Axentra Corp Limited's price-to-book ratio is 33.7x.
Axentra Corp Limited is rated Very Weak with a fundamental score of 18/100. This score is calculated from objective financial metrics
Axentra Corp Limited has a debt-to-equity ratio of N/A.
Axentra Corp Limited's return ratios over recent years
Axentra Corp Limited's operating cash flow is positive (FY2025).
Axentra Corp Limited currently does not pay a significant dividend (yield 0.00%).
Axentra Corp Limited's shareholding pattern (Feb 2026)
Axentra Corp Limited's promoter holding has decreased recently.
Axentra Corp Limited has been outperforming Nifty 500 for 5 consecutive weeks, indicating building momentum.
Axentra Corp Limited is an established outperformer with 5 weeks of consecutive Nifty 500 outperformance.
Axentra Corp Limited has 3 key growth catalysts identified from recent earnings analysis
Axentra Corp Limited has 2 key risks worth monitoring
In Q3 FY26, Axentra Corp Limited's management highlighted
Axentra Corp Limited's management has provided the following forward guidance for Q4 FY26
Based on quantitative research signals, here is why Axentra Corp Limited may be worth studying
Axentra Corp Limited investment thesis summary:
Axentra Corp Limited's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
